Nonmyeloablative matched sibling stem cell transplantation with an optional reinforced stem cell infusion for patients with hemoglobinopathies case report form

1. UPN: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2. Sex & Age

(a) male (b) female

Age: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

3. ABO blood type: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

4. Diagnosis: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(a) sickle cell disease (b) β-thalassemia major

5. Pre-transplant characteristics

(1) Serum ferritin level: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(2) Hemoglobin level: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(3) ECOG PS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(4) HCT-CI: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(5) Medication: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

6. Initial SCT-related characteristics

(1) Donor sex:

(a) male (b) female

(2) Infused cell number:

CD34+: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_, CD3+: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(3) Initial SCT date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(a) Neurophil engraftment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(b) Platelet engraftment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(4) Complications after initial SCT

(a) aGVHD: (yes/no) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(b) cGHVD: (yes/no) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

7. Reinforced SCT-related characteristics (yes/no)

(1) date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(2) Infused cell number:

CD34+: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_, CD3+: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(3) Initial SCT date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(a) Neurophil engraftment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(b) Platelet engraftment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(4) Complications after initial SCT

(a) aGVHD: (yes/no) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(b) cGHVD: (yes/no) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(c) Others: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

8. Overall outcomes

(1) Overall survival: (yes/no) date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(2) Graft failure: (yes/no) date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(3) Donor WB and T-cell chimerism

1 months \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 3 months \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 6 months \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

9 months \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 12 months \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 18 months \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

24 months \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 32 months \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 36 months \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_